StockWatch
·
HomeLiveReports

Bajaj Consumer Care Ltd Q1 FY27 Results

BAJAJCONQ1 FY27 Results
Filing
Result:Very Good· Market: FlatBroad basedMargin expansion

Outlook: Cautiously Optimistic · Guidance: None

MetricValueChangeQ1 FY26
Revenue341.57 Cr28.1%
Total Income349.60 Cr27.4%
Expenditure262.34 Cr14.6%
PBT87.27 Cr90.6%
Net Profit70.75 Cr86.5%
OPM24.41%9.12pp
NPM20.24%6.42pp
EPS5.4295.7%
View full financials

FMCG revenue grew a strong 28.1% YoY with OPM expanding ~910bps (15.3%→24.4%), driving genuine 86.5% adjusted PAT growth from both top-line and margin, not one-offs.

BAJAJ CONSUMER CARE · Q1 FY-2027 · THE VERDICT

28% Growth Hits Its Ceiling

Bajaj delivered impressive Q1 earnings—revenue up 28%, PAT up 87%—but the market sold off 18.4% by day 5. The reason: management signaled this growth is unsustainable and will normalize to low-teens, turning a strong quarter into a growth inflection warning.

02 Aug 2026 · 6 min read

The quarter in numbers

Revenue

₹341.6 Cr

+28.1% YoY, +10.8% QoQ

PAT

₹70.7 Cr

+86.5% YoY, +10.4% QoQ

EBITDA

₹84.4 Cr

Margin 24.7% (vs 12.3% prior year)

Net margin

20.2%

Call claimed 20.7% (50 bps overstated)

On paper, Q1 FY-2027 looks like a breakout quarter for Bajaj Consumer Care. Revenue of ₹341.6 crore arrived with 28% YoY growth—an acceleration from historical pattern—while PAT nearly doubled, growing 86.5% to ₹70.7 crore. EBITDA margins hit 24.7%, the high end of management's stated aspiration. The company maintained advertising intensity at 14.6% while harvesting 600 basis points in fixed-cost savings, showing operating leverage at work.

But the market's verdict was swift and harsh. After a pre-result close of ₹660.45, the stock fell 10.59% on day 1, 16.16% by day 3, and settled down 18.4% by day 5. It now sits at ₹524.1, nearly 24.26% below its all-time high of ₹692, with RSI at 21.4 (oversold). A strong earnings delivery had triggered a sharp sell-off—a mismatch that demands explanation.

The growth inflection

The culprit is not Q1's performance but Q2 and beyond. Management delivered 28% revenue growth this quarter but explicitly told analysts that this is exponential growth that will normalize as high prior-year bases lap. The long-term aspiration, restated multiple times, is double-digit to low-teens annual growth—a figure representing at least a 50% deceleration from the current run rate.

Combined with management's warning that Q2 gross margins will remain under pressure due to high-cost inventory carried forward from Q1 (a result of West Asia war-driven commodity volatility), the quarter reads as a peak rather than a trough. The market interpreted this as management pumping the brakes—and rotated out of the story.

What holds up: the fundamentals

Management's claims vs. delivered result

  • Revenue ₹341.6 Cr, +28.1% YoY growth

  • PAT ₹70.7 Cr; NPM 20.2% (call claimed 20.7%)

  • EBITDA ₹84.4 Cr, margin 24.7%, up 1240 bps YoY

  • Gross margin 61.8%, down 120 bps QoQ but up 510 bps YoY

  • ADHO volume growth low-teens (MLH-adjusted)

  • ASP +29% YoY; pricing power intact across channels

The earnings quality is sound. The company is growing through both pricing (+29% ASP YoY) and volume (low-teens for ADHO, the core 80% of revenue), with pricing power absorbed by consumers without demand destruction. Broad-based growth across channels—organized trade, general trade, rural, urban—shows this is not a one-category story. International markets rebounded sharply (Nepal, Bangladesh, MENA double-digit), offsetting FY26's weakness.

The P&L is free of one-time items. The 20.2% net margin is legitimate (call's claim of 20.7% was 50 bps overstated, a minor rounding). Operating leverage is real: fixed costs fell 600 bps YoY while revenue grew 28%, a sign of genuine scalability.

What changed on this call

Three strategic shifts in management's narrative

Gross margin trajectory

Downgrade

Q2 margins expected to remain under pressure due to high-cost inventory. Previously implied mid-60s was sustainable; now expected to dip further before recovery Q3–Q4.

Volume growth acceleration

Upgrade

ADHO volume jumped to low-teens from prior mid-single-digit run-rate, driven by smaller unit price points. Shows pricing power working at the margin.

International rebound

Upgrade

After FY26 challenges, Nepal, Bangladesh, MENA, and rest-of-world all double-digit or better. Diversification away from India base accelerating.

The market's positioning

The stock's sharp decline from ₹660.45 to ₹524.1 (day 5) is being met with selective buying. Foreign institutional investors (FII) have added 689 basis points to reach 16.59% ownership (Q4 FY26), a net positive in a falling market. Domestic institutional investors (DII), however, are trimming—down to 14.27% from 15.75% a quarter prior. Retail appears to be the net seller, spooked by guidance reset.

Volume trends are declining even as price falls—a warning that conviction to buy the dip is weak. The stock sits well below SMA20 (₹571.82) and SMA50 (₹578.2), in a downtrend, though above SMA200 (₹401.9)—the long-term uptrend is intact but severely tested.

RSI of 21.4 signals oversold conditions in the short term, historically a mean-reversion setup. But oversold does not mean cheap—it means the trend is down and any bounce will likely remain capped until management re-establishes growth credibility or Aarohan (distribution expansion) begins delivering measurable benefits.

The bull-bear debate

Risks ranked by severity

What could derail the story from here

Raw material volatility extends into Q3–Q4

High

Management expects Q2–Q3 pressure with Q4 relief. If copra, edible oils, or LLP costs stay elevated, EBITDA margins could fall to 22–23% vs 24.7%, eating ₹15–20 Cr off annualized profit.

Volume growth falters as base effects bite

High

Q1 low-teens volume sits on weak Q1 FY26 base. By Q3 FY27, bases toughen. If volume slows to mid-single-digit, reaching double-digit revenue growth becomes harder.

Aarohan execution falters or delivers no uplift

Medium

First-time deployment in four states. If distribution expansion fails to translate to volume or mix gains (200–300 bps promised), H2 narrative collapses.

Competitive intensity in coconut/Banjara's forces concessions

Medium

Growth portfolio (20% of revenue) fights Marico, Unilever in mass segments. Price war or share loss would compound margin pressure.

DII outflows accelerate

Medium

DII already trimming. If double-digit growth narrative fails, more domestic money could exit, triggering re-rating lower even if fundamentals don't deteriorate.

What to watch next

Three things that resolve the debate in Q2

  • 1 · Gross margin trend in Q2

    Will it compress further as expected, or stabilize faster? Management said Q2 will be "tougher" but didn't quantify. If it holds above 60%, relief is ahead. If it falls to 59% or below, Q3–Q4 recovery becomes uncertain.

  • 2 · ADHO volume growth sustainability

    Low-teens Q1 growth is healthy. Does it persist into Q2 with tougher base effects? If ADHO volume decelerates to single-digit, revenue growth falls sharply. ASP growth alone won't compensate.

  • 3 · Early signals on Aarohan

    Four states launched; 200–300 bps mix uplift promised. By Q2, there should be evidence of traction (outlet count, volume contribution, pricing commentary). If management stays vague, credibility of H2 recovery diminishes.

The honest close

Bajaj Consumer Care delivered a quarter that was operationally excellent but strategically sobering. The company proved it can grow revenue at 28% and drive 87% profit growth through pricing power and operating leverage—both high-quality achievements. But it also told analysts that this is a peak, not a baseline. Long-term aspiration is half the current rate.

For holders at ₹524, the stock is fairly valued but not cheap. The margin is narrow. You're buying on belief that Aarohan works, international momentum sustains, and double-digit growth is durable despite base effects and competition. None certain.

For new buyers, wait for either (a) Q2 evidence of gross margin recovery, or (b) tangible disclosure of Aarohan benefit. A bounce from oversold levels is probable; sustained rally requires narrative shift. Until then, HOLD.

The single number to track: Q2 EBITDA margin. If it stays above 24%, thesis holds. If it falls below 23%, re-rate lower. That spread, ₹5–8 crore on annualized profit, is the difference between double-digit growth that sticks and a cyclical deceleration.

Informational and educational content only. Not investment advice.

Bajaj Consumer Care Ltd (BAJAJCON) Q1 FY27 Results, Transcript & Analysis — StockWatch